Why the study?
The study was conducted to analyze the long-term safety and effectiveness of second-generation cryoballoon ablation for the treatment of AF and evaluate risk factors for recurrence.
Does second-generation cryoballoon ablation prevent atrial tachyarrhythmia recurrence in patients with drug-refractory symptomatic atrial fibrillation?
Population
760 consecutive patients with drug-refractory symptomatic AF undergoing PVI
Comparison
PVI using CB2 ablation
Design
Single-center observational cohort study
Follow-up
Mean (19 ± 8) months (through 3 years)
Key result
Second-generation cryoballoon ablation achieved 100% acute pulmonary vein isolation with a 0.9% major complication rate, and 36-month freedom from tachyarrhythmias of 63.2% in PAF and 60.9% in SAF.
Authors
Loading...
May support cryoballoon ablation in drug-refractory AF; hypothesis-generating for long-term durability pending randomized trials.
Cohort (n=760)
No
Does second-generation cryoballoon ablation prevent atrial tachyarrhythmia recurrence in patients with drug-refractory symptomatic atrial fibrillation?
Second-generation cryoballoon ablation provides high acute success and durable long-term freedom from atrial tachyarrhythmias in both paroxysmal and persistent AF, with AF course and weight gain identified as risk factors for recurrence.
Dai et al. (2022) conducted a cohort in Atrial fibrillation (n=760). Second-generation cryoballoon (CB2) ablation was evaluated on Procedure-related safety and freedom from atrial fibrillation and atrial flutter/atrial tachycardia through 3 years. Second-generation cryoballoon ablation achieved 100% acute pulmonary vein isolation with a 0.9% major complication rate, and 36-month freedom from tachyarrhythmias of 63.2% in PAF and 60.9% in SAF.